急性失代偿期心力衰竭的治疗进展  

Advances in Treatment of Acute Decompensated Heart Failure

作　　者：李欢[1] 刘地川[1] 

机构地区：[1]重庆医科大学附属第二医院心血管内科,重庆

出　　处：《临床医学进展》2023年第2期1825-1831,共7页Advances in Clinical Medicine

摘　　要：急性失代偿期心力衰竭(ADHF)是急性心力衰竭(AHF)最常见的表现形式,随着医疗技术水平的不断进步,治疗心力衰竭的新药不断被批准上市、治疗方案不断优化调整。目前ADHF的治疗目的主要包括稳定血流动力学、缓解症状和预防短期发病率和死亡率,常见的治疗包括血管扩张剂、正性肌力药、醛固酮受体拮抗剂等相关药物及机械通气、血液净化等非药物辅助治疗方法。由于ADHF的病理生理机制尚未阐明,ADHF的标准治疗方案缺乏大规模临床试验、确切的证据等研究及报道,本文从药物及非药物治疗等方面综述了ADHF的治疗现状及研究进展。Acute decompensated heart failure (ADHF) is the most common manifestation of acute heart failure (AHF), and with the continuous progress of medical technology, new drugs for heart failure continue to be approved and marketed, and treatment regimens continue to be optimized and adjusted. The common treatments include vasodilators, positive inotropic agents, aldosterone receptor antago-nists and other related drugs, as well as non-pharmacological adjuvant therapies such as mechani-cal ventilation and ultrafiltration, etc. Because the pathophysiological mechanisms of ADHF have not been elucidated, and the treatment protocols for ADHF lack large-scale clinical trials and precise evidence, this paper reviews the current status and research progress of ADHF treatment from the aspects of drug and non-drug treatments.

关 键 词：急性失代偿期心力衰竭 治疗进展 

分 类 号：R54[医药卫生—心血管疾病]